Business Context and Reporting Period
This Form 8-K Current Report for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) covers events occurring on August 5 and August 6, 2024. The company is a Delaware corporation trading on The Nasdaq Capital Market. The filing addresses a material amendment to a convertible note agreement, a stockholder-approved reverse stock split, and the status of a financial restatement.
Key Financial Metrics and Agreements
- Debt and Liquidity: The company holds a $4.3 million convertible note (the "Alto Note") with Alto Opportunity Master Fund. As of the filing date, $1.2 million remains outstanding on this note.
- Cash Collateral: On August 6, 2024, the company paid $600,000 in cash to Alto to be held as collateral against the remaining note balance.
- Payment Deferral: The monthly installment payment originally due on September 3, 2024, has been deferred until the note's maturity date of March 11, 2025.
- Capital Structure: The company approved a one-for-eight (1:8) reverse stock split, effective August 13, 2024. No fractional shares will be issued; holders entitled to fractions will receive one full share.
Material Changes and Corporate Actions
- Reverse Stock Split: Stockholders approved a reverse split ratio between 1:3 and 1:8 at the July 31, 2024 annual meeting. The Board selected a 1:8 ratio. This action reduces the number of outstanding shares and proportionately increases the exercise prices of outstanding warrants and restricted stock units.
- Financial Restatement (Reaudit): The company is restating financial statements for the years ended December 31, 2022, and 2023 due to errors. This requires the filing of amended Form 10-K/A and Form 10-Q/A reports.
- Waiver of Default: The note holder (Alto) granted a waiver regarding a default section triggered by the restatement and reaudit of the company's financial statements.
Outlook, Risks, and Management Commentary
- Equity Offering: Management intends to conduct an equity offering in the near term to fund upcoming Phase 2 clinical trials.
- Regulatory Filings: The company plans to file a registration statement on Form S-1 and a shelf registration on Form S-3. These filings are contingent upon the completion of the amended Annual Report (10-K/A), the amended Quarterly Report (10-Q/A for March 31, 2024), and the Quarterly Report for June 30, 2024.
- Risk Factors: The necessity of a reaudit indicates historical accounting errors. The company's ability to raise capital for clinical trials is currently dependent on resolving these regulatory filing requirements.
Investor Verification Checklist
- Verify the effective date of the 1:8 reverse stock split (August 13, 2024) and the new CUSIP number (825693302).
- Monitor the filing of the amended Form 10-K/A and Form 10-Q/A to understand the specific nature of the accounting errors requiring the reaudit.
- Track the progress of the planned equity offering (Form S-1/S-3) to assess funding availability for Phase 2 clinical trials.
- Confirm the status of the $1.2 million outstanding convertible note and the $600,000 cash collateral arrangement.